Qubit Pharmaceuticals

Qubit Pharmaceuticals is a pioneering deep-tech company specializing in the discovery and design of novel drug candidates for complex targets, by leveraging cutting-edge molecular simulation technologies, hybrid High-Performance Computing (HPC), and Artificial Intelligence (AI). Qubit Pharmaceuticals stands at the forefront of innovation in pharmaceutical research with their groundbreaking research in quantum computing applied to quantum chemistry that promises to revolutionize drug discovery, offering unprecedented precision and speed into identifying targets, discovering novel molecules and predicting their interactions. 

Qubit Pharmaceuticals leverages their technologies and expertise to advance 7 fully owned drug discovery programs focusing on cancer resistance and escapement, a growing concern in aging populations, and chronic inflammatory diseases. They also co-develop programs with academia and pharmaceutical partners.

Their proprietary ATLAS drug discovery platform unites their technologies based on 30 years of research from renowned scientists and founders, Louis Lagardère (Sorbonne University and CNRS), Matthieu Montes (CNAM), Jean-Philip Piquemal (Sorbonne University and CNRS), Jay Ponder (Washington University in St Louis), Pengyu Ren (University of Texas at Austin). Their multidisciplinary team of 60 experts, led by CEO Robert Marino, works from Paris, France and Boston, USA.